Total Funding
21
22
Total FundingPost-IPO Equity raised
Growth Score
1 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
158147
Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.
Cameron Durrant: Chairman & CEO
Geoffrey Yarranton: Chief Scientific Officer and Executive Vice President of Research and DevelopmentPast Role: Celltech Therapeutics, Director of Research
About the Company
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes
programs such as Lenzilumab, Ifabotuzumab, and HGen005.
